John L. Lock, PharmD

Assistant Scientific Director
AbbVie Inc

Disclosure(s): Abbvie: Employee, Stocks/Bonds

Poster(s):

• 1385 - Pathway with single-dose long-acting intravenous antibiotic dalbavancin is a cost-saving alternative to usual inpatient care of acute bacterial skin and skin structure infections (ABSSSI)
  Friday, October 21, 2022

  12:15 PM – 1:30 PM US ET